Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rockwell Medical Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Rockwell Medical kazanç ve gelirinin sırasıyla yıllık 169.8% ve 9.5% oranında artması tahmin edilirken, EPS'nin yıllık 167.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

169.8%

Kazanç büyüme oranı

167.9%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.5%
Gelir büyüme oranı	9.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	11 Sep 2024

Gelecekteki son büyüme güncellemeleri

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 11

Recent updates

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Sep 29

Rockwell Medical: The Turnaround Is Looking Real

Sep 15

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 11

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Sep 02

Rockwell Medical Q2 Earnings Preview

Aug 12

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Mar 02

Rockwell Medical: Down But By No Means Out

Oct 05

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

Jun 08

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Mar 08

Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 10

How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?

Jan 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:RMTI - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	109	2	N/A	N/A	2
12/31/2024	100	-1	N/A	N/A	2
6/30/2024	94	-5	-5	-5	N/A
3/31/2024	87	-9	-8	-8	N/A
12/31/2023	84	-9	-10	-9	N/A
9/30/2023	81	-9	-10	-10	N/A
6/30/2023	76	-12	-7	-7	N/A
3/31/2023	76	-13	-11	-11	N/A
12/31/2022	73	-19	-17	-17	N/A
9/30/2022	69	-25	-26	-26	N/A
6/30/2022	66	-29	-32	-32	N/A
3/31/2022	63	-32	-31	-31	N/A
12/31/2021	62	-33	-34	-34	N/A
9/30/2021	62	-32	-34	-33	N/A
6/30/2021	61	-32	-32	-31	N/A
3/31/2021	62	-31	-36	-36	N/A
12/31/2020	62	-31	-31	-30	N/A
9/30/2020	63	-30	-27	-26	N/A
6/30/2020	63	-30	-28	-28	N/A
3/31/2020	62	-33	-30	-28	N/A
12/31/2019	61	-34	-29	-27	N/A
9/30/2019	63	-36	-29	-28	N/A
6/30/2019	64	-33	-28	-26	N/A
3/31/2019	64	-35	-22	-21	N/A
12/31/2018	63	-32	-21	-20	N/A
9/30/2018	61	-32	-21	-19	N/A
6/30/2018	59	-32	-20	-19	N/A
3/31/2018	58	-27	N/A	-21	N/A
12/31/2017	57	-26	N/A	-21	N/A
9/30/2017	56	-22	N/A	-16	N/A
6/30/2017	54	-21	N/A	-18	N/A
3/31/2017	54	-20	N/A	-16	N/A
12/31/2016	53	-20	N/A	-12	N/A
9/30/2016	54	-21	N/A	-16	N/A
6/30/2016	56	-18	N/A	-13	N/A
3/31/2016	55	-16	N/A	-14	N/A
12/31/2015	55	-14	N/A	-13	N/A
9/30/2015	56	-15	N/A	4	N/A
6/30/2015	55	-17	N/A	8	N/A
3/31/2015	55	-17	N/A	11	N/A
12/31/2014	54	-21	N/A	4	N/A
9/30/2014	54	-23	N/A	-21	N/A
6/30/2014	53	-33	N/A	-31	N/A
3/31/2014	53	-41	N/A	-50	N/A
12/31/2013	52	-49	N/A	-51	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RMTI önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: RMTI önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: RMTI önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: RMTI şirketinin gelirinin (yıllık 9.5% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RMTI şirketinin gelirinin (yıllık 9.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RMTI 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Rockwell Medical Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond

Consensus EPS estimates fall by 35%, revenue upgraded

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Recent updates

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Rockwell Medical: The Turnaround Is Looking Real

New minor risk - Share price stability

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond

Rockwell Medical, Inc. Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity

New major risk - Financial position

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

New major risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Forecast to breakeven in 2025

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus estimates of losses per share improve by 15%

Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million.

New major risk - Share price stability

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Consensus estimates of losses per share improve by 13%

Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023

Price target decreased to US$5.00

Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Consensus estimates of losses per share improve by 24%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical Q2 Earnings Preview

Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$19.00

Rockwell Medical, Inc. Provides Clinical Update

Rockwell Medical, Inc. announced that it has received $14.9 million in funding

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022

Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China

Rockwell Medical, Inc. announced delayed annual 10-K filing

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Forecast to breakeven in 2023

Price target decreased to US$4.00

Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 3Q 2020)